SGLT2 Inhibitors – The New HF Therapies on the Block
Published: 25 August 2020
21m 5sPart 5 Panel discussion
2m 46sPart 1 Welcome & Introductions Subodh Verma
20m 55sPart 2 A Brief History of SGLT2 Inhibitors Subodh Verma
12m 55sPart 3 What Have We Learned About SGLT2 Inhibitors? A Clinical Perspective Nikolaus Marx
In this Educational Symposium from the e-SPACE Heart Failure Global Web-Conference, Subodh Verma, Nikolaus Marx and Shelley Zieroth discuss SGLT2 inhibitors covering their history, a clinical perspective into what we have learned about them and how future trials might affect clinical practice.
- Raise Awareness of SGLT2 Inhibitors as Cardiovascular Therapies With Cardio–Renal Benefits
- Highlight Appropriate Patients for Initiation of an SGLT2 Inhibitor and Share With Cardiologists the Well-Established Safety Profile and Clinical Considerations for SGLT2 Inhibitor Treatment
- Inform Cardiologists of the Current Evidence and Ongoing Trials for SGLT2 Inhibitors in Patients With HF
- 5 mins - Welcome & introduction - Subodh Verma
- 15 mins - A brief history of SGLT2 inhibitors - Subodh Verma
- 15 mins - What have we learned about SGLT2 inhibitors? A clinical perspective - Nikolaus Marx
- 15 mins - How might future trials affect how I might treat my patients? - Shelley Zieroth
- 10 mins - Faculty discussion (pre-recorded) - All Faculty
- Close - Subodh Verma
- Live Q&A and discussion - All Faculty
More from this programme
What Have We Learned About SGLT2 Inhibitors? A Clinical Perspective
How Might Future Trials Affect How I Treat My Patients?
Director of the Heart Failure and Heart Transplant Clinics
Dr Shelley Zieroth is Professor at the College of Medicine, Max Rady Faculty of Health Sciences, University of Manitoba, as well as Director of the Heart Failure and Heart Transplant Clinics at St. Boniface Hospital in Winnipeg, CA.
She is also Head of the Medical Heart Failure Program for Cardiac Sciences Manitoba. She is involved in several heart failure clinical trials as a PI, National Lead or Executive Committee member. She is the Immediate Past President of the Canadian Heart Failure Society and Co-Chair of the Canadian Cardiovascular Society Heart Failure Guidelines. She serves as Co-Chair of Canada’s largest annual heart failure meeting, HF Update and serves as Scientific Planning Committee Chair for the Canadian Cardiovascular Congress hosted by the Canadian Cardiovascular Society. She is currently President-elect of the Federation of Medical Women of Canada.